Studied in a phase III trial vs an established regimen

ABRAXANE phase 3 trial design for metastatic breast cancer
End points assessed in  this trial
  • The primary efficacy end point assessed was reconciled target lesion response rate (recTLRR)
    • recTLRR was based on independent radiologic assessment of tumor responses
    • recTLRR was reconciled with investigator-reported responses and includes only responses achieved in the first 6 cycles of therapy
  • Secondary efficacy end points included overall response rate, time to disease progression, and overall survival, among other measures1

The approved indication for ABRAXANE is the same as that for paclitaxel injection for metastatic breast cancer2

ECOG=Eastern Cooperative Oncology Group.

Studied in a phase III trial vs an established regimen

ABRAXANE phase 3 trial design for metastatic breast cancer
End points assessed in
  this trial
  • The primary efficacy end point assessed was reconciled target lesion response rate (recTLRR)
    • recTLRR was based on independent radiologic assessment of tumor responses
    • recTLRR was reconciled with investigator-reported responses and includes only responses achieved in the first 6 cycles of therapy
  • Secondary efficacy end points included overall response rate, time to disease progression, and overall survival, among other measures1

The approved indication for ABRAXANE is the same as that for paclitaxel injection for metastatic breast cancer2

ECOG=Eastern Cooperative Oncology Group.

INDICATION

ABRAXANE is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated.

INDICATION

ABRAXANE is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated.